Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Apotex: Amgen's Biosimilar Lawsuit's A Sham, Predatory

This article was originally published in Scrip

Executive Summary

Amgen's patent infringement lawsuit filed in August against Apotex involving its pegfilgrastim biosimilar, which is referenced on the former company's long-acting human granulocyte colony-stimulating factor Neulasta, is a "sham" and part of an "overall predatory scheme to monopolize the relevant market," the latter company charged in court documents filed this week.

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts